mRNA Treatment Market Revenue (US$ Mn) by Product Type
mRNA Treatment Market Revenue (US$ Mn) Based on Therapeutic Area
mRNA Treatment Market Revenue (US$ Mn) Based on Route of Administration
mRNA Treatment Market Revenue (US$ Mn) Based on Region
Europe mRNA Treatment Market Revenue (US$ Mn) by Country
North America mRNA Treatment Market Revenue (US$ Mn) by Country
Asia Pacific mRNA Treatment Market Revenue (US$ Mn) by Country
Latin America mRNA Treatment Market Revenue (US$ Mn) by Country
Middle East & Africa mRNA Treatment Market Revenue (US$ Mn) by Country
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global mRNA Treatment Market Snapshot
Chapter 4. Global mRNA Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Industry Analysis – Porter’s Five Forces Analysis
4.6. Clinical Trial/Pipeline Analysis
4.7. COVID 19 Impact Analysis on Healthcare Industry
Chapter 5. Market Segmentation 1: Product Type Estimates & Trend Analysis
5.1. Product Type & Market Share, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Product Type:
5.2.1. mRNA Vaccines
5.2.2. mRNA Therapeutic
Chapter 6. Market Segmentation 2: Therapeutic Area Estimates & Trend Analysis
6.1. Therapeutic Area & Market Share, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Therapeutic Area:
6.2.1. Infectious Diseases
6.2.2. Oncological Disorders
6.2.3. Other Disorders
Chapter 7. Market Segmentation 3: Route of Administration Estimates & Trend Analysis
7.1. Route of Administration & Market Share, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following Route of Administration:
7.2.1. Intravenous
7.2.2. Intramuscular
7.2.3. Intranasal
7.2.4. Others
Chapter 8. mRNA Treatment Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America mRNA Treatment Market revenue (US$ Million) estimates and forecasts by Product Type, 2024-2031
8.1.2. North America mRNA Treatment Market revenue (US$ Million) estimates and forecasts by Therapeutic Area, 2024-2031
8.1.3. North America mRNA Treatment Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2024-2031
8.1.4. North America mRNA Treatment Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe mRNA Treatment Market revenue (US$ Million) by Product Type, 2024-2031
8.2.2. Europe mRNA Treatment Market revenue (US$ Million) by Therapeutic Area, 2024-2031
8.2.3. Europe mRNA Treatment Market revenue (US$ Million) by Route of Administration, 2024-2031
8.2.4. Europe mRNA Treatment Market revenue (US$ Million) by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific mRNA Treatment Market revenue (US$ Million) by Product Type, 2024-2031
8.3.2. Asia Pacific mRNA Treatment Market revenue (US$ Million) by Therapeutic Area, 2024-2031
8.3.3. Asia Pacific mRNA Treatment Market revenue (US$ Million) by Route of Administration, 2024-2031
8.3.4. Asia Pacific mRNA Treatment Market revenue (US$ Million) by country, 2024-2031
8.4. Latin America
8.4.1. Latin America mRNA Treatment Market revenue (US$ Million) by Product Type, 2024-2031
8.4.2. Latin America mRNA Treatment Market revenue (US$ Million) by Therapeutic Area, 2024-2031
8.4.3. Latin America mRNA Treatment Market revenue (US$ Million) by Route of Administration, 2024-2031
8.4.4. Latin America mRNA Treatment Market revenue (US$ Million) by country, (US$ Million) 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa mRNA Treatment Market revenue (US$ Million) by Product Type, 2024-2031
8.5.2. Middle East & Africa mRNA Treatment Market revenue (US$ Million) by Therapeutic Area, 2024-2031
8.5.3. Middle East & Africa mRNA Treatment Market revenue (US$ Million) by Route of Administration 2024-2031
8.5.4. Middle East & Africa mRNA Treatment Market revenue (US$ Million) by country, (US$ Million) 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. CureVac
9.2.2. Moderna
9.2.3. BioNTech (Pfizer)
9.2.4. Translate Bio(Sanofi)
9.2.5. Ethris (AstraZeneca)
9.2.6. Kernal Biologics
9.2.7. Silence Therapeutics
9.2.8. eTheRNA (Etherna Immunotherapies)
9.2.9. Tiba Biotechnology
9.2.10. In-Cell-Art
9.2.11. Anima Biotech
9.2.12. H3 Biomedicine Inc.
9.2.13. Arcturus Therapeutics
9.2.14. eFFECTOR Therapeutics, Inc.
9.2.15. Ionis Pharmaceuticals, Inc.
9.2.16. Stemirna Therapeutics Co., Ltd.
9.2.17. Skyhawk Therapeutics, Inc.
9.2.18. RNAimmune (Sirnaomics)
9.2.19. Ziphius Therapeutics NV
9.2.20. miRagen Therapeutics, Inc.
9.2.21. GlaxoSmithKline plc
9.2.22. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.